Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

The signs of mental illness vary depending on the person, risk factors, and mental disorder. Learn which visible and hidden ...

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

Depression is more than just a mental struggle — it has deep biochemical roots. Oxidative stress can disrupt the gut microbiome, worsening inflammation and altering brain function. Scientists have now ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...